The marketing partner (Eisai ESALY.PK) for Arena's (ARNA) obesity-fighting Belviq has petitioned...

The marketing partner (Eisai ESALY.PK) for Arena's (ARNA) obesity-fighting Belviq has petitioned the DEA to expedite its approval process. If granted (this sort of request is rarely denied), this could have the drug in pharmacies on February 7, writes Joe Dedvukaj. Combined with what looks to be imminent EU approval, Street analysts will find themselves needing to catch up to lofty sales figures.

Comments (3)
  • tjellal
    , contributor
    Comment (1) | Send Message
    this is the best X-Mas gift we can get. 20$ pps is in very near future.
    24 Dec 2012, 08:56 AM Reply Like
  • deercreekvols
    , contributor
    Comments (9513) | Send Message
    Most analysts have missed on Arena in a major way.


    It seems that they took the word of Mr. Cramer instead of performing due diligence.


    Institutional buys tells a very different story on Arena.


    I am long ARNA and will enjoy an even better Christmas on this news.
    24 Dec 2012, 11:45 AM Reply Like
  • johnsnare
    , contributor
    Comments (19) | Send Message
    How high is up.?
    24 Dec 2012, 04:20 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs